Aktie A0RC46 CUMBERLAND PHARMACEUTICALS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Cumberland Pharmaceuticals Inc.

Aktien

A0RC46

US2307701092

CPIX

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 03.05.2024 		% 5 Tage % 1. Jan.
1.58 USD +4.64% Intraday Chart für Cumberland Pharmaceuticals Inc. -10.23% -11.82%
05.03. Cumberland Pharmaceuticals Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
05.03. Transcript : Cumberland Pharmaceuticals Inc., 2023 Earnings Call, Mar 05, 2024

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.
Cumberland Pharmaceuticals : CEO Message
Cumberland Pharmaceuticals : CEO Message
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cumberland: Q4 Earnings Snapshot
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cumberland: Q3 Earnings Snapshot
Cumberland Pharmaceuticals Seeks Acquisitions
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.02
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 Revenue $10.1M
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0RC46 Aktie
  4. Nachrichten Cumberland Pharmaceuticals Inc.
  5. Andere Sprachen